DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,200 filers reported holding DANAHER CORPORATION in Q1 2018. The put-call ratio across all filers is 0.54 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $39,182,851 | +0.4% | 157,931 | -2.9% | 0.11% | +1.8% |
| Q2 2023 | $39,026,774 | -23.2% | 162,611 | -19.3% | 0.11% | -26.2% |
| Q1 2023 | $50,817,661 | -4.7% | 201,625 | +0.4% | 0.15% | -10.2% |
| Q4 2022 | $53,299,051 | -0.9% | 200,810 | -3.5% | 0.17% | -6.7% |
| Q3 2022 | $53,773,000 | +18.6% | 208,189 | +16.4% | 0.18% | +24.5% |
| Q2 2022 | $45,350,000 | -12.1% | 178,882 | +1.7% | 0.14% | +4.4% |
| Q1 2022 | $51,576,000 | -12.0% | 175,827 | -1.2% | 0.14% | +1.5% |
| Q4 2021 | $58,580,000 | +7.3% | 178,049 | -0.7% | 0.14% | +1.5% |
| Q3 2021 | $54,614,000 | +12.2% | 179,392 | -1.1% | 0.13% | +10.8% |
| Q2 2021 | $48,683,000 | +18.0% | 181,408 | -1.0% | 0.12% | +8.1% |
| Q1 2021 | $41,248,000 | -0.1% | 183,258 | -1.4% | 0.11% | -6.7% |
| Q4 2020 | $41,300,000 | +5.0% | 185,915 | +1.7% | 0.12% | -16.2% |
| Q3 2020 | $39,351,000 | +22.3% | 182,747 | +0.4% | 0.14% | +6.0% |
| Q2 2020 | $32,185,000 | +29.4% | 182,009 | +1.3% | 0.13% | -5.6% |
| Q1 2020 | $24,869,000 | -10.7% | 179,679 | -1.0% | 0.14% | +6.0% |
| Q4 2019 | $27,847,000 | +4.2% | 181,440 | -1.9% | 0.13% | -3.6% |
| Q3 2019 | $26,712,000 | +0.3% | 184,946 | -0.8% | 0.14% | -1.4% |
| Q2 2019 | $26,639,000 | +6.1% | 186,386 | -2.0% | 0.14% | -1.4% |
| Q1 2019 | $25,106,000 | +51.3% | 190,170 | +18.2% | 0.14% | +25.4% |
| Q4 2018 | $16,598,000 | -23.0% | 160,953 | -18.9% | 0.11% | -9.5% |
| Q3 2018 | $21,558,000 | +10.0% | 198,399 | -0.1% | 0.13% | 0.0% |
| Q2 2018 | $19,595,000 | +0.4% | 198,565 | -0.4% | 0.13% | -13.7% |
| Q1 2018 | $19,511,000 | +0.4% | 199,277 | -4.8% | 0.15% | -7.6% |
| Q4 2017 | $19,429,000 | +6.8% | 209,325 | -1.3% | 0.16% | -3.7% |
| Q3 2017 | $18,194,000 | -0.5% | 212,104 | -2.1% | 0.16% | -10.4% |
| Q2 2017 | $18,287,000 | -3.3% | 216,686 | -2.0% | 0.18% | -11.2% |
| Q1 2017 | $18,911,000 | +7.0% | 221,106 | -2.6% | 0.21% | -2.4% |
| Q4 2016 | $17,679,000 | -3.6% | 227,114 | -2.9% | 0.21% | -7.9% |
| Q3 2016 | $18,335,000 | +8.9% | 233,898 | +40.3% | 0.23% | -9.8% |
| Q2 2016 | $16,833,000 | +4.7% | 166,664 | -1.7% | 0.25% | -2.7% |
| Q1 2016 | $16,075,000 | +0.5% | 169,462 | -1.6% | 0.26% | -1.1% |
| Q4 2015 | $15,997,000 | +7.5% | 172,225 | -1.4% | 0.26% | +4.3% |
| Q3 2015 | $14,882,000 | -2.1% | 174,654 | -1.7% | 0.25% | +7.2% |
| Q2 2015 | $15,201,000 | -0.8% | 177,597 | -1.6% | 0.24% | -0.4% |
| Q1 2015 | $15,323,000 | -2.9% | 180,486 | -2.0% | 0.24% | -9.9% |
| Q4 2014 | $15,783,000 | +10.0% | 184,140 | -2.5% | 0.26% | +2.7% |
| Q3 2014 | $14,345,000 | -6.6% | 188,806 | -3.2% | 0.26% | -2.3% |
| Q2 2014 | $15,351,000 | +3.0% | 194,982 | -1.9% | 0.26% | +0.4% |
| Q1 2014 | $14,909,000 | -5.3% | 198,783 | -2.5% | 0.26% | -1.1% |
| Q4 2013 | $15,744,000 | +8.6% | 203,939 | -2.4% | 0.26% | -2.9% |
| Q3 2013 | $14,491,000 | +7.1% | 209,047 | -2.2% | 0.27% | -0.7% |
| Q2 2013 | $13,536,000 | – | 213,846 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |